NEW HAVEN, Conn., June 15, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in fireside chats at two upcoming virtual investor conferences.
Presentation Details:
Event: BMO 2020 Prescriptions for Success Healthcare Conference
Date: Tuesday, June 23, 2020
Time: 8:30 AM ETEvent: BofA Securities Napa Biopharma Conference
Date: Wednesday, June 24, 2020
Time: 7:30 AM PT/10:30 AM ETLive webcasts from the BMO and BofA fireside chats will be accessible through the Investors section of the Company’s website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.About BioXcel Therapeutics, Inc.:BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.Contact Information:BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.comInvestor Relations:
John Graziano
[email protected]
1.646.378.2942Media:
Julia Deutsch
[email protected]
1.646.378.2967
Bay Street News
